Stay updated with breaking news from Bruce Cree. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Separate analysis also being presented at ECTRIMS 2022 reinforces the efficacy of UPLIZNA in patients with genetic variations -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced new data
Press release content from Business Wire. The AP news staff was not involved in its creation.
Inebilizumab is effective for neuromyelitis optica spectrum disorder, even among patients who are genetically at risk for reduced response to anti-CD20 therapies, new research suggests.
-- Data being presented at the CMSC Annual Meeting demonstrates UPLIZNA may reduce attack risk and disability among populations with genetic variables typically linked to poor treatment response
-- Separate analysis being presented at the AAN Annual Meeting shows UPLIZNA reduced pain associated with NMOSD over three years -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation